Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 ...
In recent weeks, Abbott Laboratories raised its quarterly dividend for the 52nd consecutive year and secured CE Mark approval ...
Jan 22 (Reuters) - Abbott forecast current-quarter profit below estimates after missing Wall Street expectations for ...
Abbott missed Wall Street estimates for quarterly revenue on Thursday, hit by weakness in its diagnostic business which has been volatile due to sharp decline in COVID-19 testing demand and a freeze ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback